| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.4 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |